Cichowski, Karen

A negative feedback signaling network underlies oncogene-induced senescence

Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell

Telomeres, Telomerase, and SenescenceProtein Kinase Regulation and GTPase Signaling

Cited by 501

Many roads lead to oncogene-induced senescence

Courtois-Cox, S., Jones, S. L., & Cichowski, K. (2008) · Oncogene

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 397

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 378

Elucidating Distinct Roles for NF1 in Melanomagenesis

Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery

Melanoma and MAPK PathwaysNeurofibromatosis and Schwannoma Cases

Cited by 258

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors

De Raedt, T., Walton, Z., Yecies, J. L., Li, D., Chen, Y., Malone, C. F., Maertens, O., Jeong, S. M., Bronson, R. T., Lebleu, V., et al. (2011) · Cancer Cell

Protein Kinase Regulation and GTPase SignalingEndoplasmic Reticulum Stress and Disease

Cited by 258

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS -, and NF1 -Mutant Melanomas

Maertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery

Melanoma and MAPK PathwaysChromatin Remodeling and Cancer

Cited by 95

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

Nardi, F., Perurena, N., Schade, A. E., Li, Z.-H., Ngo, K., Ivanova, E. V., Saldanha, A., Li, C., Gokhale, P. C., Hata, A. N., et al. (2023) · Journal of Clinical Investigation

Lung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

Cited by 21